<DOC>
	<DOCNO>NCT00760149</DOCNO>
	<brief_summary>In phase II clinical trial , pharmacokinetics , safety ( short-term ) efficacy high standard dos rifampicin study intensive phase tuberculosis ( TB ) treatment . Patients enrol study either get standard TB regimen ( include 600 mg rifampicin ; first study arm ) , 900 mg rifampicin plus isoniazid , ethambutol pyrazinamide standard dosage ( second study arm ) , 1200 mg rifampicin plus drug standard dosage ( third study arm ) . All patient get standard TB regimen continuation phase treatment .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics High Versus Standard Dose Rifampicin Patients With Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Participant newly diagnose pulmonary tuberculosis , confirm positive smear least two sputum specimen ZN stain . Participant willing test HIV . Participant least 18 , 65 year age day first dose study medication . Participant admit KNTH KCMC intensive phase TB treatment . Participant able willing attend KNTH KCMC regularly continuation phase TB treatment . Participant able understand willing sign Informed Consent Form prior screen evaluation . Female participant understand important get pregnant study . They agree take measure prevent get pregnant study . They agree take measure prevent get pregnant , use contraceptive device barrier method . Participant treat antituberculosis drug past three year . Participant 's body weight less 50 kg . Participant abnormal liver function test serum creatinine ( defined level higher upper limit normal ) . Participant relevant medical history current condition might interfere drug absorption , distribution , metabolism excretion ( i.e . chronic gastrointestinal disease , Diabetes Mellitus , renal hepatic disease , use concomitant drug interfere pharmacokinetics antiTB drug ) . Participant antiretroviral treatment inclusion . Participant CD4 count le 350 cells/mm3 . Participant Karnofsky score less 40 . Participant pregnant breastfeeding . Participant Multi Drug Resistant ( MDR ) TB another standard treatment regimen need .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>rifampicin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>